Amycretin vs Orforglipron
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Zenagamtide, NNC0487-0111
Amycretin is Novo Nordisk's single-molecule agonist of both the GLP-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. Early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the AMAZE program) in 2026. It is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks.
Also: LY3502970, OWL833
Orforglipron is Eli Lilly's oral, once-daily GLP-1 receptor agonist, and the headline is that it is a small molecule, not a peptide, so it survives the gut and can be taken as a plain pill with no food or water restrictions. It is being developed for type 2 diabetes and obesity and has completed multiple successful Phase 3 trials. As of mid-2026 it is filed for regulatory review but not yet approved.
Key Comparison Insights
- Orforglipron is FDA approved, while Amycretin remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Orforglipron has stronger research evidence (FDA Approved) compared to Amycretin (Human Trials).
Detailed Comparison
| Attribute | Amycretin | Orforglipron |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Amycretin hits two appetite systems at once. The GLP-1 side slows stomach emptying, boosts insulin release after meals, and dampens appetite in the brain, the same biology behind semaglutide. The amylin side mimics a hormone your pancreas releases alongside insulin, which acts on the brainstem to make you feel full sooner and also curbs glucagon after eating. Novo combined these two signals in one molecule rather than mixing two drugs (which is what its CagriSema combination does). The bet is that the two pathways add together, giving more weight loss than either alone. That idea fits the early data, but it has not yet been tested head-to-head against semaglutide or tirzepatide in a large trial. | Orforglipron activates the same GLP-1 receptor that injectable drugs like semaglutide target, which curbs appetite, slows stomach emptying, and triggers insulin release when blood sugar is high. The difference is chemistry. Semaglutide is a fragile peptide that the digestive tract chews up, which is why it normally needs an injection or a specially formulated pill taken on an empty stomach. Orforglipron is a non-peptide small molecule engineered to bind the same receptor while being stable enough to swallow like any other tablet. Same biological lever, far more convenient delivery. |
| Common Dosing | Trial doses of 1.25-40 mg once weekly (injection) Once weekly (injection) or once daily (tablet) | Limited community data available See research protocols |
| Administration | Subcutaneous injection once weekly, or oral tablet once daily (separate formulations) | Oral tablet daily |
| Typical Duration | 20-36 weeks in published trials; phase 3 runs longer | Long-term use expected |
| Best Time to Take | Same day each week (injection); trial protocols set timing for the tablet | Any time of day, same time daily |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Two early trials were published in The Lancet in June 2025. In the subcutaneous phase 1b/2a trial (125 adults with overweight or obesity), the estimated weight loss assuming full adherence was 24.3% at 60 mg over 36 weeks and 22.0% at 20 mg over 36 weeks, versus roughly flat weight on placebo, with no plateau by the end of treatment. A separate phase 1 trial of the oral tablet (144 people, 12 weeks) showed up to 13.1% loss at the highest dose. In November 2025 Novo reported a 36-week phase 2 trial in 448 adults with type 2 diabetes: up to 14.5% weight loss with weekly injections (2.6% on placebo), up to 10.1% with the daily pill, and HbA1c drops of up to 1.8 points. Side effects were mostly gastrointestinal, dose-related, and mild to moderate. Novo moved both forms into phase 3; AMAZE 1 (weekly injection at 1.25, 5, 20 or 40 mg versus placebo, about 1,150 people without diabetes) is registered as NCT07339423 with completion expected in 2029. Honest caveats: the headline numbers come from small trials using an efficacy estimand that assumes everyone stayed on drug, and long-term safety is unknown. | The evidence base here is strong and recent, anchored by large Phase 3 programs. In the obesity ATTAIN-1 trial (72 weeks), all three doses beat placebo for weight loss, and full results were published in the New England Journal of Medicine. ATTAIN-2, in adults with obesity and type 2 diabetes, was published in The Lancet and showed clinically meaningful weight loss plus improvements in waist circumference, blood pressure, non-HDL cholesterol, and triglycerides. On the diabetes side, ACHIEVE-1 was the first Phase 3 win for any oral small-molecule GLP-1 drug, and in the head-to-head ACHIEVE-3 trial orforglipron beat oral semaglutide on both A1C and weight. Side effects mirror the rest of the GLP-1 class: mostly nausea, vomiting, and diarrhea, generally mild to moderate. The realistic read is that this is a genuine breakthrough in delivery rather than a brand-new mechanism, and approval decisions are expected to follow the completed filings. |
Frequently Asked Questions: Amycretin vs Orforglipron
What is the difference between Amycretin and Orforglipron?
Amycretin is a weight loss peptide that amycretin is novo nordisk's single-molecule agonist of both the glp-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the amaze program) in 2026. it is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks. Orforglipron is a weight loss peptide that orforglipron is eli lilly's oral, once-daily glp-1 receptor agonist, and the headline is that it is a small molecule, not a peptide, so it survives the gut and can be taken as a plain pill with no food or water restrictions. it is being developed for type 2 diabetes and obesity and has completed multiple successful phase 3 trials. as of mid-2026 it is filed for regulatory review but not yet approved. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Amycretin or Orforglipron?
Neither is universally "better" - the choice depends on your specific goals. Amycretin is typically used for weight loss purposes, while Orforglipron is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Amycretin and Orforglipron be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Amycretin and Orforglipron together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.